Skip to content

Advertisement

BMC Complementary and Alternative Medicine

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Naringenin attenuates hepatitis B virus X protein-induced hepatic steatosis

Contributed equally
BMC Complementary and Alternative MedicineBMC series – open, inclusive and trusted201717:505

https://doi.org/10.1186/s12906-017-2019-2

Received: 24 July 2017

Accepted: 20 November 2017

Published: 28 November 2017

Abstract

Background

Naringenin (Nar), a common dietary flavonoid abundantly present in fruits, vegetables, and Chinese herbs, is believed to possess strong anti-inflammatory properties and to modulate hepatic apolipoprotein and lipid synthesis. However, there are no reports describing Nar’s effects on the hepatitis B virus protein X (HBx) -induced hepatic steatosis, and the detailed molecular mechanisms of the compound’s effects are still unclear.

Methods

Nar was administered by oral gavage to HBx-transgenic mice from 4 to 6 weeks of age. Mice were sacrificed after 14 days of once-daily naringenin administration. Liver tissues and sera were collected for histopathology and biochemical analysis.

Results

Nar counteracted hepatic lipid accumulation and liver dysfunction in HBx-transgenic mice. In addition, Nar significantly decreased expression of adipogenic and lipogenic genes in mice, suggesting that the compound may have therapeutic effects in the early stages of HBx-mediated hepatic steatosis. These results indicated that naringenin inhibits HBx-induced expression of hepatic adipogenic and lipogenic genes through suppression of HBx-induced gene expression, including decreases in the transcriptional activity of SREBP1c, LXRα, and PPARγ in HBx-trangenic mice and HBx-transfected HepG2 cells.

Conclusions

Results from this study suggested that Nar may serve as a therapeutic agent for preventing HBx-infected hepatic steatosis in humans.

Keywords

HBxNaringeninHepatic steatosisSREBP1cLXRαPPARγCD36AdiponectinaP2FAS

Background

The hepatitis B virus (HBV) is strongly associated with hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) [14]. Fatty liver disease has been recognized as a risk factor for HCC development [5]. The prevalence of hepatic steatosis has been shown to be associated with chronic HBV infection [6]. The gene encoding the HBV X protein (HBx) is located at the 3′ end of the single-stranded portion of the HBV genome; this segment integrates into host DNA during hepatocellular regeneration after each out-break of hepatitis, resulting in increased intracellular accumulation of HBx [7]. Accumulation of HBx can cause lipid accumulation in hepatocytes [6] and in HBx-transgenic mice [8]. The induction of pathogenesis of hepatic steatosis by HBV is mediated by the sterol regulatory element binding protein 1 (SREBP-1) and the peroxisome proliferator-activated receptor (PPAR) [6], resulting in transcriptional activation via the PI3K/AKT/PTEN pathway or by protein–protein interactions. The liver X receptor (LXR) controls genes that encode proteins associated with de novo lipogenesis, including SREBP1c, ACC1 (acetyl-CoA carboxylase 1), and FAS (fatty acid synthase) [9]. In the liver, LXR also controls the transcription of the gene encoding cholesterol 7-α-hydroxylase 1 (CYP7A1), a protein that is involved in the conversion of cholesterol into bile acids [10].

Many herbals and phytochemicals have been considered as potential therapeutic agents for the treatment of HCC [1116]. Naringenin (Nar) is a common dietary flavonoid that is plentiful in fruits and vegetables. The compound also is abundant in herbs [17]. Several studies have shown that Nar possesses a variety of pharmacological effects, such as antioxidant activity [18], anti-inflammatory activities [19], anti-tumour-invasion activity [20], and regulation of apolipoprotein and lipid synthesis [21]. Nar counteracts the induction of lipogenesis genes in rats maintained on a high-fat diet or in a fasted-like state [22, 23]. However, there are no reports (to our knowledge) on the mechanism of Nar’s effects on HBx-induced hepatic steatosis. Therefore, in the present study, we investigated the potential therapeutic effects of Nar on HBV-associated liver damage and fatty liver accumulation in HBx-transgenic mice.

Methods

Reagents

HBx-transgenic mice

The HBx-transgenic mouse model was obtained from Professor Ting-Fen Tsai, National Yang Ming University. The Tsai laboratory constructed this model by introducing (into the C57BL/6 background) a copy of the HBx-encoding gene under the control of the liver-specific albumin promoter [24]. In the present study, all of the animal experiments used male mice of the line A106 in the C57BL/6 background [25]. The animals were housed (5 per cage) in a temperature-controlled room with an uninterrupted 12-h/12-h light/dark cycle. Animals were provided with free access to tap water and food throughout the experiments. All mouse manipulations were performed according to a study-specific protocol (No. 1041001–1) approved by the Institutional Animal Care and Use Committees of the Dalin Tzu Chi Hospital (Chia-Yi, Taiwan).

Nar administration

To study the therapeutic effect of Nar on the fatty liver and early stage of liver pathogenesis, four-week-old HBx-transgenic male mice were randomly assigned to three groups of five animals each. Naringenin (CAS Number 67604-48-2 from Sigma R5010; Nar) was of >98% purity, dissolved in 100% ethanol at a concentration of 50 mM and stored at 20 °C. 30 mg/kg/d of Nar was dissolved in H2O and delivered to the mice by oral administration using a feeding needle once a day. Nar administered to the mice over 14 days of once-daily oral gavage (p. o.) using a feeding needle, at a dose 30 mg/kg. Mice were sacrificed under general anesthesia by inhalation of 3% isoflurane at 14 days after Nar administration. At necropsy, liver tissues and sera were collected for histopathology and biochemical analysis. The sera were frozen at −80 °C pending assay; separate segments of each liver sample were fixed in formalin or flash frozen at −80 °C pending further processing.

Histopathologic analysis

Liver specimens were processed using standard methods. The formalin-fixed liver samples were embedded in paraffin and sectioned; the resulting slides were stained with hematoxylin–eosin (H&E) and evaluated by light microscopy. Frozen liver samples were sectioned using a cryotstat; the resulting slides were stained with Oil red-O and evaluated by light microscopy to detect fat accumulation [8].

Cell culture

Cells of the human hepatoma cell line HepG2 (Bio Resource Collection and Research Centre, Taiwan) were propagated in Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT, USA). The cells were transiently transfected with 5 μg of plasmid DNA using SuperFect Transfection Reagent (Qiagen, Valencia, CA, USA). The resulting stable HepG2 transfectants (HepG2-HBx), which carried a construct providing doxycycline (DOX) -inducible expression of a HBx-green fluorescent protein (GFP) fusion protein (HBx-GFP), were maintained in complete Minimal Essential Medium (MEM) supplemented with 100 μg/mL G418 and 50 μg/mL hygromycin. HepG2-HBx cells were resuspended in medium (100 μL/well) in 96-well plates and cultured with or without DOX and various concentrations of Nar. The viability of the treated HepG2-HBx cells was determined by MTT assay.

RNA isolation and RT-PCR analysis

Total RNA was isolated from mouse tissues and stable HepG2-HBx cells using TRIzol Reagent (Life Technology). Gene expression was quantified using semi-quantitative reverse transcription-polymerase chain reaction (PCR) analysis as described previously [26]. The reverse transcription step was performed with 2 μg of total RNA using oligo-d(T) as primer and Superscript III reverse transcriptase (Invitrogen Life Technologies). Real-time reverse transcription PCR (RT-PCR) analyses were conducted on a Roche LightCycler 480 instrument using a TaqMan probe. All amplifications were performed in triplicate for each RNA sample, and all experiments were carried out using RNA samples from 3 separate mice; total input cDNA was equalized for all samples. RT-PCR results for each reaction were normalized against an internal control consisting of the transcription of a house-keeping gene (encoding hypoxanthine phosphoribosyltransferase (HPRT)). The PCR primers are listed in Table 1. The intensity of band on the gel was calculated by Gel-Pro® Analyzer (Media Cybernetics, Inc., Silver Spring, MD).
Table 1

Oligonucleotide primer sets and conditions used for semi-quantitative RT-PCR

Primer-name

Sequence

PPARyl-Forward

5′-TCTCCATGACAGACATGGACA-3’

PPARyl-Reverse

5′-GTCAGG CTGTTG GTCTCACA-3’

PPARy2-Forward

5′-GGGTGAAACTCTGGGAGATTCTC-3’

PPARy2-Reverse

5′-TCAGCAACCATTGGGTCAG-3’

PPARa-Forward

5′-GCAGCTCGTACAGGTCATCA-3’

PPARa-Reverse

5′-ACTGCCGTT GT CT GT CACT G-3’

SREBP-lc-Forward

5′-TTGTGGAGCTCAAAGACCTG-3’

SREBP-lc-Reverse

5′-TGCAAG AAGCGG AT GT AGTC-3’

LXRa-Forward

5′-TCCTACACGAGGATCAAGCG-3’

LXRa-Reverse

5′-AGTCGCAATGCAAAGACCTG-3’

GAPDH-Forward

5′-AGAACATCATCCCTG CAT CC-3’

GAPDH-Reverse

5′-CACATTGGGGGTAGGAACAC-3’

HBx-Forward

5′-TgTgCT gCCAACTggAT CCTg-3’

HBx-Reverse

5′-CCAATTTATgCCTACAgCCTCC-3’

Preparation of nuclear extracts and electrophoretic mobility shift assay (EMSA)

HepG2-HBx cells were treated with 10–40 μM naringenin. Nuclear extracts were prepared as described previously [27]. Biotinylated electrophoretic mobility shift assays (EMSAs) were performed as previously described [28].

Western blot analysis

Liver tissues from each mouse were homogenized at 4 °C in extraction buffer (100 mM Tris-HCl, pH 7.4, 5 mM EDTA, 50 mM NaCl, 50 mM sodium pyrophosphate, 50 mM NaF, 100 mM orthovanadate, 1% Triton X-100, 1 mM phenylmethanosulfonylfluoride, 2 mg/mL aprotinin, 1 mg/mL pepstatin A, and 1 mg/mL leupeptin) and centrifuged at 3000×g for 15 min at 4 °C. HepG2-HBx cells were lysed in 250 μL of sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM dithiothreitol, and 0.1% bromophenol blue). The amount of proteins in the tissue lysate and cell lytsate were assayed using the Bradford assay. Proteins (40 μg/sample for homogenized tissue, 10 μg/sample for cell lysates) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and protein bands were transferred electrophoretically to nitrocellulose membranes. Membranes were probed with polyclonal antibodies against SREBP1 (Santa Cruz Biotechnology, Santa Cruz, CA), GFP, AKT, AKT-p, PI3K, PI3K-p, C/EBPα, and β-actin (as a loading control) (Cell Signaling Technology, Beverly, MA, USA). Bound antibodies were detected using peroxidase-conjugated anti-rabbit antibodies followed by chemiluminescence assay (ECL System; Amersham, Buckinghamshire, UK) and autoradiographic exposure. The intensity of band on the bolts was calculated by Gel-Pro® Analyzer (Media Cybernetics, Inc., Silver Spring, MD).

Statistical analysis

Two-tailed one-way analysis of variance (ANOVA) was used to identify significant differences between the means (p < 0.05). If the means differed significantly, a post-hoc Tukey-Kramer test was used to compare the groups. Data are shown as the mean ± standard error of the mean (SEM).

Results

Naringenin promotes recovery from fatty liver in HBx-transgenic mice

To investigate the effects of Nar (30 mg/kg/d, which corresponds to a daily dose that would be feasible in human) on HBx-induced hepatic lipid accumulation, we assessed the hepatic lipid content of liver tissues from HBx-transgenic mice. At an early stage of the HBx-mediated disease, 6-week-old vehicle-dosed HBx-transgenic mice exhibited liver pathology including fat accumulation, ballooning of the hepatocytes, and abnormal arrangements of the sinusoid [Fig. 1b(ii)]. Oral administration of Nar (30 mg/kg/d) to HBx-transgenic mice resulted in decreased liver damage and significant recovery of liver pathology [Fig. 1b (iii)] compared with the WT control [Fig. 1b (i)]. Oil-red O staining of liver sections showed that fatty liver was no longer seen in the HBx-transgenic mice administered Nar for 14 days [Fig. 1b (vi)]. There was no significant difference in the body weight or in the ratio of liver to body weight in the HBx-transgenic mice with or without Nar (data not shown).
Fig. 1

Treatment with naringenin (Nar) reverses fatty liver and early-stage liver damage in HBx-transgenic mice. a Schematic timeline of the treatment protocol. Animals were genotyped at 3 weeks of age. Starting at 4 weeks of age, HBX-transgenic mice (n = 5 per group) were dosed by 14 days of once-daily oral gavage with Nar (30 mg/kg) or an equivalent volume of vehicle (phosphate-buffered saline, PBS); wild-type (WT) littermates (n = 5) were dosed on the same schedule with vehicle. b Representative micrographs of hematoxylin and eosin (H&E) –stained sections of liver sections from a vehicle-dosed WT mouse (i), a vehicle-dosed HBx-transgenic mouse (ii), and a Nar-dosed HBx-transgenic mouse (iii), or representative micrographs of Oil red-O–stained sections of liver sections from animals of the same groups [(iv), (v), and (vi), respectively]. Original magnification, H&E 200×, oil red-O staining, 400×. c The levels of serum parameters for liver function [alanine aminotransferase (ALT) (i) and aspartate aminotransferase AST (ii)], renal function [blood urea nitrogen (BUN) (iii) and creatinine (Cre) (iv)], and lipid chemistry [total cholesterol (CHOL) (v) and triglycerides (TG) (vi)] were measured in vehicle-dosed WT mice, vehicle-dosed HBx-transgenic mice, and Nar-dosed HBx-transgenic mice. Values are expressed as mean ± SD. #, p < 0.05 between vehicle-treated WT and HBx-transgenic mice, *, p < 0.05 between HBx-transgenic vehicle- and Nar-treated mice

The values for serum ALT and AST in the HBx-transgenic mice were significantly decreased after 14 days of Nar dosing (compared to control HBx mice) [Fig. 1c (i, ii)]. Notably, no significant difference was detected in the serum BUN and creatinine values in the HBx-transgenic animals with and without Nar treatment [Fig. 1c (iii, iv)]. Consistent with those results, the serum cholesterol and TG levels were significantly elevated in HBx-transgenic mice compared to WT mice and to HBx-transgenic mice that received Nar treatment [Fig. 1c (v, vi)]. Thus, our results showed that Nar treatment attenuated fatty liver pathology in the HBx-transgenic mice, indicating that this compound has therapeutic effects during the early stages of liver pathogenesis in this model.

Effect of naringenin on HBx-induced expression of adipogenic and lipogenic genes in HBx-transgenic mice

Next, we tested whether the overexpression of HBx is sufficient to decrease the hepatic lipid accumulation. The expression of adipogenic, and lipogenic–related genes were detected by RT-PCR in HBx-transgenic mice (Fig. 2). The levels of RNAs encoding FAS and ACC, downstream target genes of SREBP1 transcriptional control, were elevated in HBx-transgenic mice compared to the levels in WT mice. The levels of these transcripts in the HBx-transgenic mice were attenuated in HBx-transgenic animals dosed with Nar for 14 days. Similarly, transcripts encoding CD36, adiponectin, and aP2, all targets of PPARγ activity, accumulated to higher levels in HBx-transgenic mice, and this effect was attenuated in HBx-transgenic dosed with Nar for 14 days. However, levels of the mRNA encoding PPARα (and of PPARα protein) were not changed significantly in HBx-transgenic mice (compared to WT mice). Together, these observations indicated that Nar treatment counteracts HBx-induced expression of adipogenic and lipogenic genes, consistent with the decreased hepatic lipid accumulation observed with Nar dosing.
Fig. 2

The effect of naringenin on the expression of adipogenic and lipogenic genes in 8-week-old HBx-transgenic mice. RT-PCR data are representative of 5 independent experiments

Effect of naringenin on lipid accumulation and cell viability in HepG2-HBx cells

To examine the effect of Nar on lipid accumulation under in vitro conditions, we first confirmed the effect of DOX induction on the expression of a HBx-GFP fusion in hepatic (HepG2) cells. GFP-fusion-protein expression was monitored using fluorescence microscopy, which detects fluorescence of the GFP protein (Fig. 3a), and by western blot analysis using an anti-GFP antibody (Fig. 3b). Both techniques showed that the GFP-fusion protein was detected only in the presence of DOX, demonstrating that the DOX-regulated HBx-GFP fusion had been successfully transfected into the recipient cells. The cytotoxicity of the HBx-GFP construct and that of Nar treatment were evaluated using the MTT assay. No cytotoxic effects were observed in HepG2-HBx cells exposed to 25–100 μM Nar in the absence of DOX; cell numbers were slightly decreased in the presence of DOX (Fig. 3c). Lipid accumulation (as assessed by Oil Red-O staining) was significantly decreased in DOX-induced HepG2-HBx cells exposed to 50 μg/mL Nar (and in uninduced (no-DOX) HepG2-HBx cells) when compared to that in DOX-induced HepG2-HBx cells grown in the absence of Nar (Fig. 3a). Thus, Nar also counteracted the HBx-associated lipid accumulation in an in vitro model, without apparent cytotoxicity.
Fig. 3

Establishment of constitutive HBx expression and Oil red-O staining in HepG2 cells. HepG2 cells were transfected with pRT-HBx-GFP. HepG2-HBx-GFP cells with and without DOX were observed under a fluorescence microscope (a). Expression of the HBx-GFP fusion protein in HepG2-HBx-GFP cells with and without DOX treatment (DOX(−) and DOX(+), respectively) was determined by western blot analysis using a GFP-specific antibody. β-actin was included as an internal control (b) After selection of G418-resistant colonies, cell proliferation with and without DOX treatment and with and without naringenin (Nar, at the indicated concentrations) was assessed by MTT assay (c). HepG2-HBx-GFP cells with and without DOX were treated with or without Nar at the indicated concentrations for 24 h. Intracellular lipid droplets in HepG2 cells were stained with Oil Red O and visualized by light microscopy (Olympus, Tokyo, Japan) (d)

Nar inhibits the expression of lipogenic genes in HBx-transgenic mice and HepG2-HBx cells

To discover the molecular mechanisms underlying the beneficial effects of Nar on HBx-mediated fatty liver at the early stage of liver damage, we investigated the expression of lipogenic genes in liver by reverse transcriptase PCR and RT-PCR (Fig. 4a–c). Previous reports showed that the expression of HBx (in HBx-transgenic mice) induces expression of LXR, and of lipogenic proteins (e.g. Srebp1-c and PPARγ) encoded by genes regulated by LXR [9, 29] We observed that Nar dosing of HBx-transgenic mice decreased the expression of mRNAs encoding PPARγ and LXRα, but had no significant effect on Srebp-1c transcript levels (Fig. 4a). We confirmed these results in HepG2-HBx cells: exposure 50 or 100 μM Nar yielded significant decreases in the accumulation of PPARγ and LXRα mRNAs, while the effects on Srebp-1c transcript levels did not achieve significance (Fig. 4b). We further evaluated the effects of Nar by examining (separately) the nuclear translocation of Srebp1c and the DNA-binding activity of the protein. In control cells (grown without the DOX inducer), the majority of Srebp-1c was retained in cytoplasm; in contrast, the induction of HBx expression (by growth in the presence of Dox) resulted in increased translocation of Srebp-1c to the nucleus. Notably, growth in the presence of both DOX and Nar yielded nominally dose-dependent decreases in nuclear Srebp-1c (Fig. 4d). Similarly, biotinylated EMSAs showed that expression of HBx enhanced the DNA-binding activity of SREBP1, while Nar exposure yielded nominally dose-dependent decreases in this activity (Fig. 5b).
Fig. 4

The effect of naringenin (Nar) on the expression of genes associated with lipogenesis in the HBx-transgenic livers. a Expression of the mRNAs encoding PPARγ, SREBP1-c, and LXRα in the livers of wild-type (WT) mice and in the livers of HBx-transgenic mice without and with 14 days of once-daily Nar treatment (30 mg/kg/d), as assessed by RT-PCR. b Expression of the mRNAs encoding PPARγ, SREBP1-c, and LXRα in HepG2 cells that had been mock-transfected (mock), or stably transfected with the HBx-GFP construct (HA) and grown in the presence of 0, 25, 50, or 100 μM Nar, as assessed by real-time PCR. c Repeat of the experiment portrayed in Panel A, this time using reverse transcription-PCR. Amplification products were electrophoresed, stained with ethidium bromide, and visualized using a transilluminator. d Nar attenuates HBx-induced nuclear translocation of the SREBP1 protein in HepG2-HBx cells. HepG2-HBx cells were grown in the absence of inducer (DOX(−)) or in the presence of inducer and Nar at 0 (DOX(+)), 25, 50, or 100 μM Nar. After 24 h of growth, cells were harvested, and the nuclear extract (NE) and cytoplasmic (Cyto) fractions were generated and processed for immunodetection of the SREBP1 protein as described in the Methods section. e Nar attenuates HBx-induced activation of the SREBP1 protein in HepG2-HBx cells. Cultures were grown as in Panel d, and samples collected after 24un hours were processed for biotinylated electrophoretic mobility shift assays as described in the Methods section. For Panels a and b, data are presented as mean ± SD from each group of 5 animals. Asterisk indicates a significant difference (p < 0.05 by two-tailed unpaired t test) comparing HBX mouse ± Nar or HepG2-HBx ± Nar. For Panels c, d, and e, reactions were performed with samples from individual mice or cultures; results are representative of those seen for biological replicates

Fig. 5

Effect of naringenin on HBx-induced AKT- signaling pathways. HepG2-HBx-GFP cells were pretreated with 0–100 μM naringenin before incubation with DOX for 45 min. Whole-cell lysates were then prepared and subjected to western blot analysis using antibodies specific for phosphorylated PI3K, AKT, and C/EBPα

Inhibitory effect of naringenin on HBx-induced activation of PI3K/AKT and C/EBPα

To further elucidate the mechanism of Nar activity, we examined the effect of the compound on crosstalk among the PI3K, AKT, and C/EBPα pathways in HepG2-HBx cells. Previous work showed that HBx can enhance PPAR gene expression through C/EBPα activation [6, 30]. Therefore, we examined whether the HBx-induced expression of C/EBPα was influenced by Nar. As expected, C/EBPα protein levels were increased in DOX-treated HepG2-HBx cells; additional exposure to Nar yielded apparently dose-dependent attenuation of C/EBPα protein accumulation (Fig. 4).

Previous work also showed that PPARγ promotes metabolic adaptations downstream of the PI3K/Akt pathway that favor hepatocyte steatosis [31]. Therefore, we investigated the effects of Nar on HBx-induced PI3K/Akt activity in HepG2-HBx cells. Western blot analysis revealed that the DOX-induced HBx expression resulted in apparent increases in the levels of phosphorylated PI3K and Akt (p-PI3K and p-Akt, respectively) compared to those in DOX-untreated controls, without obviously altering the accumulation of the proteins (phosphorylated + unphosphorylated) themselves. Exposure to Nar attenuated the amounts of the phosphorylated species in a nominally dose-dependent fashion (Fig. 5).

Discussion

Hepatic steatosis (fatty liver) is associated with hepatitis virus infection, various drugs, and multiple genetic defects in energy metabolism. Fatty liver is an important factor in liver damage, and results in a further progression to cirrhosis and HCC [32]. HBx has been reported to be associated with HBV-related pathogenesis [33] and related to the development of hepatic steatosis in patients with HBV infections [4, 24]. As demonstrated in the present study, Nar exhibits therapeutic effects on the early stages of HBx-induced hepatic steatosis, attenuating fatty liver as assessed by histopathology, serum chemistry, and gene expression.

The accumulation of free fatty acids (FFAs) and cholesterol in the liver results in the production of reactive oxygen species (ROS) and tumour necrosis factor (TNFα) -mediated inflammation [34]. In the process of hepatic synthesis of endogenous fatty acids (FAs), ACC1 and FAS produce TGs, which are stored or rapidly metabolized. CD36 is the major FA transporter and enhances FFA uptake in hepatocytes [35]. LXRα, along with SREBP1c (the major isoform in the liver), affects the transcription of the genes encoding ACC1 and FAS, and that of its own gene, consequently stimulating hepatic lipogenesis [9, 36]. LXRα regulates the induction by HBx of SREBP1-mediated hepatic lipid synthesis and accumulation [9]. Separately, the transcriptional regulator PPARγ controls adipogenesis and plays a major role in the process of lipid storage. HBx also reinforces the transcriptional activity of PPARγ1 and γ2, resulting in increased expression of the CD36 gene and adipogenic genes, including adiposin, aP2, and adiponectin [6]. HBx affects various lipid metabolic pathways and lipid deposition in liver. A previous study demonstrated that Nar significantly lowers serum triacylglycerol and cholesterol levels and decreases the expression of various lipogenic genes and SREBP-1c in HFD [23]. Separate work showed that Nar modulates the activity of PPARγ and LXRα, thereby downregulating the expression of FAS [22]. In the present study, we showed that Nar attenuates the HBx-induced accumulation of the transcripts encoding FAS, ACC1, CD36, adiponectin, aP2, PPAR1γ, PPARγ2, and LXRα in the in vivo model of HBx-transgenic mice. We further demonstrated, using the in vitro model of HepG2-HBx cells, that Nar exposure counteracts HBx-induced nuclear translocation and DNA-binding activity of SREBP.

Moreover, a previous study suggested that the activation of Akt is involved in the HBx-regulated process of survival and the activation of Srebp1c in the liver [37]. In hepatocytes, PPARγ may play a predominant role in the metabolic adaptation downstream of PI3K/Akt2 pathway, leading to steatosis [31] HBx also increases the expression of PPARγ, an effect thought to result from C/EBPα activation [6]. Our results demonstrated that Nar exposure results in a significant attenuation of the HBx-induced accumulation of p-Akt, p-PI3K, and C/EBPα in HepG2-HBx cells, suggesting molecular mechanisms whereby Nar counteracts lipid accumulation in hepatocytes both in vivo and in vitro. Specifically, Nar appears to suppress lipogenesis by decreasing LXRα-Srebp1c signaling and, thus, suppresses the expression of downstream genes (such as ACC and FAS) regulated by this pathway. This decrease in LXRa-Srebp1c signaling apparently attenuates hepatic PPARγ overexpression, thereby providing hepatic protection from FFA-mediated damage in HBx-transgenic mice dosed with Nar.

Conclusions

The present study demonstrated that Nar significantly reduced hepatic lipid accumulation and liver dysfunction in HBx-transgenic mice (Fig. 6). Furthermore, Nar significantly decreased expression of adipogenic and lipogenic genes in HBx-transgenic mice and in HepG2-HBx cell culture, suggesting that Nar may have chemotherapeutic effects on the early stages of HBx-induced hepatic steatosis. These results indicated that Nar may inhibit the HBx-induced expression of hepatic adipogenic and lipogenic genes by suppressing HBx-mediated gene expression and attenuating the transcriptional activity of LXRα, SREBP1c, and PPARγ in HBx-transgenic mice and stably transfected HepG2-HBx cells. Nar may serve as a therapeutic agent for preventing HBx-infected hepatic steatosis in humans.
Fig. 6

Schematic diagram illustrates the molecular mechanism of Nar attenuated HBx-induced liver steatosis

Abbreviations

ACC1: 

Acetyl-CoA carboxylase 1

EMSA: 

Electrophoretic mobility shift assay

FAS: 

Fatty acid synthase

HBV: 

Hepatitis B virus

HBx: 

Hepatitis B X protein gene

HCC: 

Hepatocellular carcinoma

LXRα: 

Liver X receptor alpha

Nor: 

Naringenin

PPAR: 

Peroxisome proliferator-activated receptor

SREBP1: 

Sterol regulatory element binding protein 1

Declarations

Acknowledgements

This work was supported by grant DTCRD105-I-02-1 from the Buddhist Dalin Tzu Chi General Hospital, Taiwan. The authors thank Dr. Ting-Fen Tsai (National Yang–Ming University) for providing the HBx-transgenic mouse strain.

Funding

This work was supported by grant DTCRD105-I-02-1 from the Buddhist Dalin Tzu Chi General Hospital, Taiwan.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Authors’ contributions

H-J L, I-S L, and CC-Y made substantial contributions to conception and design of the experiments, or to acquisition, analysis, or interpretation of the data; H-J L, K-L K, and CC-Y were involved in drafting or critically revising the manuscript for important intellectual content; CC-Y and H-J L gave final approval of the version to be published. All authors agree to be accountable for all aspects of the work, and will ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All animal experiments, including mouse manipulations (e.g. dosing and bleeding), were performed under a protocol (number 1041001–1) approved by the Institutional Animal Care and Use Committees of the Dalin Tzu Chi hospital (Chia-Yi, Taiwan).

Consent for publication

Not applicable.

Competing interests

All authors declare that there are no financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial, or other) to declare in relation to this manuscript or this study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
School of Post-baccalaureate Chinese Medicine, Tzu Chi University
(2)
Department of Chinese Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
(3)
School of Post-baccalaureate Chinese Medicine, China Medical University
(4)
Division of Chinese Internal Medicine, China Medical University Hospital

References

  1. Tiollais P, Charnay P, Vyas GN. Biology of hepatitis B virus. Science. 1981;213(4506):406–11.View ArticlePubMedGoogle Scholar
  2. Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, et al. Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial. Hepatol Int. 2009;3(3):445–52.View ArticlePubMed CentralPubMedGoogle Scholar
  3. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25(1):142–63.View ArticlePubMed CentralPubMedGoogle Scholar
  4. Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Chan HY, Woo J, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56(3):533–40.View ArticlePubMedGoogle Scholar
  5. Rich N, Singal AG. Nonalcoholic fatty liver disease-related hepatocellular carcinoma: a potential new challenge for hepatocellular carcinoma surveillance. Gastroenterology. 2016;151(6):1246–8.View ArticlePubMedGoogle Scholar
  6. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, Kim HH, Yang US, DY Y, Cheong J, Hepatitis B. Virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology. 2007;132(5):1955–67.View ArticlePubMedGoogle Scholar
  7. Wang WL, London WT, Lega L, Feitelson MA. HBxAg in the liver from carrier patients with chronic hepatitis and cirrhosis. Hepatology. 1991;14(1):29–37.View ArticlePubMedGoogle Scholar
  8. Teng CF, Hsieh WC, Yang CW, HM S, Tsai TF, Sung WC, Huang W, IJ S. A biphasic response pattern of lipid metabolomics in the stage progression of hepatitis B virus X tumorigenesis. Mol Carcinog. 2016;55(1):105–14.View ArticlePubMedGoogle Scholar
  9. Kim K, Kim KH, Kim HH, Cheong J, Hepatitis B. Virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem J. 2008;416(2):219–30.View ArticlePubMedGoogle Scholar
  10. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 1998;93(5):693–704.View ArticlePubMedGoogle Scholar
  11. Lee KH, Yeh MH, Kao ST, Hung CM, Liu CJ, Huang YY, Yeh CC. The inhibitory effect of hesperidin on tumor cell invasiveness occurs via suppression of activator protein 1 and nuclear factor-kappaB in human hepatocellular carcinoma cells. Toxicol Lett. 2010;194(1–2):42–9.View ArticlePubMedGoogle Scholar
  12. Wang SD, Chen BC, Kao ST, Liu CJ, Yeh CC. Genistein inhibits tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. BMC Complement Altern Med. 2014;14:26.View ArticlePubMed CentralPubMedGoogle Scholar
  13. Fan SH, Wang YY, Lu J, Zheng YL, DM W, Li MQ, Hu B, Zhang ZF, Cheng W, Shan Q. Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome. PLoS One. 2014;9(2):e89961.View ArticlePubMed CentralPubMedGoogle Scholar
  14. Chen K, Zhang S, Ji Y, Li J, An P, Ren H, Liang R, Yang J, Li Z. Baicalein inhibits the invasion and metastatic capabilities of hepatocellular carcinoma cells via down-regulation of the ERK pathway. PLoS One. 2013;8(9):e72927.View ArticlePubMed CentralPubMedGoogle Scholar
  15. Tsai TY, Livneh H, Hung TH, Lin IH, MC L, Yeh CC. Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open. 2017;7(1):e014571.View ArticlePubMed CentralPubMedGoogle Scholar
  16. YC S, Lin IH, Siao YM, Liu CJ, Yeh CC. Modulation of the tumor metastatic microenvironment and multiple signal pathways by Prunella Vulgaris in human hepatocellular carcinoma. Am J Chin Med. 2016;44(4):835–49.View ArticleGoogle Scholar
  17. Liu L, Shan S, Zhang K, Ning ZQ, XP L, Cheng YY. Naringenin and hesperetin, two flavonoids derived from Citrus Aurantium, up-regulate transcription of adiponectin. Phytother Res. 2008;22(10):1400–3.View ArticlePubMedGoogle Scholar
  18. Pietta PG. Flavonoids as antioxidants. J Nat Prod. 2000;63(7):1035–42.View ArticlePubMedGoogle Scholar
  19. Esmaeili MA, Alilou M. Naringenin attenuates CCl induced hepatic inflammation by the activation of Nrf2 mediated pathway in rats. Clin Exp Pharmacol Physiol. 2014;Google Scholar
  20. Yen HR, Liu CJ, Yeh CC. Naringenin suppresses TPA-induced tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015;235:1–9.View ArticlePubMedGoogle Scholar
  21. Lin Y, Vermeer MA, Bos W, van Buren L, Schuurbiers E, Miret-Catalan S, Trautwein EA. Molecular structures of citrus flavonoids determine their effects on lipid metabolism in HepG2 cells by primarily suppressing apoB secretion. J Agric Food Chem. 2011;59(9):4496–503.View ArticlePubMedGoogle Scholar
  22. Goldwasser J, Cohen PY, Yang E, Balaguer P, Yarmush ML, Nahmias Y. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha. PLoS One. 2010;5(8):e12399.View ArticlePubMed CentralPubMedGoogle Scholar
  23. Hashimoto T, Ide T. Activity and mRNA levels of enzymes involved in hepatic fatty acid synthesis in rats fed Naringenin. J Agric Food Chem. 2015;63(43):9536–42.View ArticlePubMedGoogle Scholar
  24. BK W, Li CC, Chen HJ, Chang JL, Jeng KS, Chou CK, Hsu MT, Tsai TF. Blocking of G1/S transition and cell death in the regenerating liver of hepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun. 2006;340(3):916–28.View ArticleGoogle Scholar
  25. Lin HC, Chen YF, Hsu WH, Yang CW, Kao CH, Tsai TF. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila). 2012;5(7):952–62.View ArticleGoogle Scholar
  26. Kao ST, Liu CJ, Yeh CC. Protective and immunomodulatory effect of flos Lonicerae japonicae by augmenting IL-10 expression in a murine model of acute lung inflammation. J Ethnopharmacol. 2015;168:108–15.View ArticlePubMedGoogle Scholar
  27. Yeh CC, Lin CC, Wang SD, Hung CM, Yeh MH, Liu CJ, Kao ST. Protective and immunomodulatory effect of Gingyo-san in a murine model of acute lung inflammation. J Ethnopharmacol. 2007;111(2):418–26.View ArticlePubMedGoogle Scholar
  28. Lin HJ, Kao ST, Siao YM, Yeh CC. The Chinese medicine Sini-san inhibits HBx-induced migration and invasiveness of human hepatocellular carcinoma cells. BMC Complement Altern Med. 2015;15:348.View ArticlePubMed CentralPubMedGoogle Scholar
  29. Na TY, Shin YK, Roh KJ, Kang SA, Hong I, SJ O, Seong JK, Park CK, Choi YL, Lee MO, Liver X. Receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2009;49(4):1122–31.View ArticlePubMedGoogle Scholar
  30. Shieh YS, Chang YS, Hong JR, Chen LJ, Jou LK, Hsu CC, Her GM. Increase of hepatic fat accumulation by liver specific expression of hepatitis B virus X protein in zebrafish. Biochim Biophys Acta. 2010;1801(7):721–30.View ArticlePubMedGoogle Scholar
  31. Panasyuk G, Espeillac C, Chauvin C, Pradelli LA, Horie Y, Suzuki A, Annicotte JS, Fajas L, Foretz M, Verdeguer F, et al. PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat Commun. 2012;3:672.View ArticlePubMed CentralPubMedGoogle Scholar
  32. Gong Z, Tas E, Yakar S, Muzumdar R. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging. Mol Cell Endocrinol. 2016;Google Scholar
  33. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84–101.View ArticlePubMedGoogle Scholar
  34. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013;59(3):583–94.View ArticlePubMedGoogle Scholar
  35. Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, Garcia-Mediavilla MV, Fernandez-Bermejo M, Lozano-Rodriguez T, Vargas-Castrillon J, Buque X, Ochoa B, Aspichueta P, et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 2011;60(10):1394–402.View ArticlePubMedGoogle Scholar
  36. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res. 2001;40(6):439–52.View ArticlePubMedGoogle Scholar
  37. Lee YI, Kang-Park S, Do SI, Lee YI. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem. 2001;276(20):16969–77.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement